Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about PACLITAXEL: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | PACLITAXEL |
| Key Genes/Proteins | AKT, CREB, HNRNPA1 |
| Related Diseases | AUTOPHAGY, CANCER, EMT, NEUROPATHY, PANCREATIC CANCER |
graph TD
PACLITAXEL["PACLITAXEL"]
PACLITAXEL -->|"causes"| Chemotherapy_Induced_Periphera["Chemotherapy-Induced Peripheral Neuropathy"]
PACLITAXEL -->|"interacts"| Irinotecan["Irinotecan"]
PACLITAXEL -->|"upregulates"| ATAD3A["ATAD3A"]
PACLITAXEL -->|"treats"| Nasopharyngeal_Carcinoma["Nasopharyngeal Carcinoma"]
PACLITAXEL -->|"causes"| ROS["ROS"]
Irinotecan -->|"interacts"| PACLITAXEL
CISPLATIN["CISPLATIN"] -->|"activates"| PACLITAXEL
CANCER["CANCER"] -->|"activates"| PACLITAXEL
NEUROPATHY["NEUROPATHY"] -->|"activates"| PACLITAXEL
AUTOPHAGY["AUTOPHAGY"] -->|"inhibits"| PACLITAXEL
CREB["CREB"] -->|"inhibits"| PACLITAXEL| Target | Relation | Type | Str |
|---|---|---|---|
| Chemotherapy-Induced Peripheral Neuropathy | causes | disease | 0.95 |
| Mitochondrial fragmentation | causes | process | 0.95 |
| DRP1 | upregulates | protein | 0.90 |
| Irinotecan | interacts_with | drug | 0.88 |
| Nasopharyngeal Carcinoma | treats | disease | 0.85 |
| ATAD3A | upregulates | protein | 0.85 |
| MFN1 | downregulates | protein | 0.85 |
| MFN2 | downregulates | protein | 0.85 |
| ROS | causes | phenotype | 0.65 |
| NEUROPATHY | causes | disease | 0.65 |
| HNRNPA1 | activates | gene | 0.65 |
| AKT | associated_with | gene | 0.50 |
| CISPLATIN | associated_with | drug | 0.45 |
| CANCER | associated_with | disease | 0.45 |
| ROS | associated_with | phenotype | 0.45 |
| DOCETAXEL | associated_with | drug | 0.45 |
| VINCRISTINE | associated_with | drug | 0.45 |
| HNRNPA1 | associated_with | gene | 0.45 |
| BORTEZOMIB | associated_with | drug | 0.45 |
| NEUROPATHY | associated_with | disease | 0.45 |
| AUTOPHAGY | associated_with | phenotype | 0.45 |
| CREB | associated_with | gene | 0.45 |
| ROS | activates | protein | 0.35 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Irinotecan | interacts_with | drug | 0.88 |
| AKT | synergizes_with | gene | 0.65 |
| AKT | inhibits | gene | 0.65 |
| IRINOTECAN | synergizes_with | drug | 0.60 |
| CISPLATIN | activates | drug | 0.50 |
| PANCREATIC CANCER | associated_with | disease | 0.50 |
| CARBOPLATIN | associated_with | drug | 0.45 |
| OXALIPLATIN | associated_with | drug | 0.45 |
| VINCRISTINE | associated_with | drug | 0.45 |
| EMT | associated_with | phenotype | 0.45 |
| CISPLATIN | associated_with | drug | 0.45 |
| BORTEZOMIB | associated_with | drug | 0.45 |
| NEUROPATHY | associated_with | disease | 0.45 |
| CANCER | associated_with | disease | 0.45 |
| CREB | associated_with | gene | 0.45 |
| 5-FLUOROURACIL | associated_with | drug | 0.45 |
| DOCETAXEL | associated_with | drug | 0.45 |
| AUTOPHAGY | associated_with | phenotype | 0.45 |
| CANCER | activates | disease | 0.35 |
| NEUROPATHY | activates | disease | 0.35 |
| AUTOPHAGY | inhibits | process | 0.35 |
| CREB | inhibits | gene | 0.35 |
| CISPLATIN | protects_against | drug | 0.35 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| No targeting hypotheses | |||
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning PACLITAXEL in their description or question text
No additional research found